PS Targeting is HUGE and Avid Bioservices CDMO has the deal mostly completed with about 15% royalties on net sales but there may be a surprise to come on those fronts...depends on what Oncologie does or refuses to do...
For now, Eli Lilly / Omeros now has some of the facts that will prove the protein pathways DEPEND upon PS Targeting ....
Elsid...now you may have your volume Spike and here is a bonus for the weekend as I would not have expected this news till next week
Further BONUS...There are others hopping on this PS Targeting trail and Oncologie? The hell with them if they can't get their heads out of the sand(box) and move this along NOW
There is a network of NEW IIS that don't want me saying much but now, we have another wave front that will push this to new levels that some Big Pharma will not like....the 9-11 first responders are all soon being connected to the info and Big Pharma types HIDING Lung Cancer new treatment that DEPENDS on PS Targeting and you think all the reporters will accept dying or money or nondisclosures?? NO WAY
Merck Keytruda was helped HUGELY by Bavituximab, a PS Targeting drug...with those approvals based on them Biomarkers...going to Avid Bioservices CDMO on about 15% royalties net sales
More to come...but the reporters and ALL that were down in Manhattan at the towers that witnessed the death tolls will not accept the death of PS Targeting by Big Pharma. Trust me...Big Pharma may have gotten their way for the past hundred years but times have changed and MANY have access to equipment that PROVES the MOA of many drugs...and why would the FDA refuse to verify special requests?? Ex Eli Lilly ...now head of Health and Human Services that is responsible for over $800M ++ in funds will also have decisions to make but know this...many will look Stafford foolish, knowing the facts are coming that prove PS Targeting gives all the most optimal immune response to have a fighting chance. The Enlightenment Age of Disease is what I have called it for years...
Since I work for no one ...and have not signed any non disclosure ...here you go
John Springs Stafford was hired by who?
Ampersand Capital was promised what?
The late Dr Phil Thorpe spent his life on helping Millions fight back disease to cancer and his PS Targeting patents will hopefully be known world wide ...soon and all those that ever signed a non disclosure to agree to stop fighting for the most optimal immune response may change their minds to speak now
_____
Omeros to Present GPR174 Data at Upcoming American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy
1 hr ago
SEATTLE--(BUSINESS WIRE)--Nov 8, 2019--
Omeros Corporation (Nasdaq: OMER) today announced an upcoming presentation entitled "Phosphatidylserine suppresses T cells through GPR174, and co-inhibition of adenosine receptors and GPR174 synergistically enhances T-cell responses" at the American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy, which is being held November 17 - 20, 2019 in Boston, Massachusetts.
Marc Gavin, Ph.D., Omeros Director of Immunology, will present the companys new findings that phosphatidylserine, a product of cell stress and death that is abundant in the tumor microenvironment (TME), directly stimulates GPR174 and attenuates T-cell responses.
Adenosine, another product of the TME, is well known to stimulate the same suppressive pathways through different GPCRs, and inhibition of both pathwaysâ??with adenosine receptor antagonists and with Omeros novel GPR174 inhibitors results in maximal enhancement of T-cell function, which should translate to effective resistance to the immunosuppressive nature of the TME.
The data will also feature new findings from animal tumor models, which validate GPR174 inhibition for cancer immunotherapy.
Designated B45, the poster will be presented in Poster Session B on Tuesday, November 19, 4:30 p.m. to 7:00 p.m.
About Omeros Corporation
Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. In addition to its commercial product OMIDRIA (phenylephrine and ketorolac intraocular solution) 1%/0.3%, Omeros has multiple Phase 3 and Phase 2 clinical-stage development programs focused on complement-mediated disorders and substance abuse, as well as a diverse group of preclinical programs including GPR174, a novel target in immuno-oncology that modulates a new cancer immunity axis recently discovered by Omeros. Small-molecule inhibitors of GPR174 are part of Omeros proprietary G protein-coupled receptor (GPCR) platform through which it controls 54 new GPCR drug targets and their corresponding compounds. The company also exclusively possesses a novel antibody-generating platform.
News 
Market Data 
Discover 
